Archives of Pharmacal Research

, Volume 37, Issue 8, pp 972–977

Anti-Helicobacter pylori xanthones of Garcinia fusca

Authors

  • Jannarin Nontakham
    • Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of ScienceSrinakharinwirot University
  • Napaporn Charoenram
    • Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of ScienceSrinakharinwirot University
  • Wanchalerm Upamai
    • Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of ScienceSrinakharinwirot University
  • Malai Taweechotipatr
    • Department of Microbiology, Faculty of MedicineSrinakharinwirot University
    • Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of ScienceSrinakharinwirot University
Research Article

DOI: 10.1007/s12272-013-0266-4

Cite this article as:
Nontakham, J., Charoenram, N., Upamai, W. et al. Arch. Pharm. Res. (2014) 37: 972. doi:10.1007/s12272-013-0266-4

Abstract

A new geranylated xanthone derivative, fuscaxanthone I (1), along with nine xanthones (29 and 11), a biphenyl (10) and three biflavonoids (1214) were isolated from the roots of Garcinia fusca Pierre. Compounds 8, 10 and 1114 were reported from this plant species for the first time. Their structures were elucidated by spectroscopic analyses, including 1D- and 2D-NMR and MS. The isolated compounds were evaluated for antibacterial activity against Helicobacter pylori. Cowaxanthone (5) and fukugiside (14) exhibited stronger inhibitory activity against H. pylori DMST reference strain at MICs 4.6 and 10.8 μM, respectively, than that of the control metronidazole. Isojacareubin (8) displayed the most potent activity against H. pylori HP40 clinical isolate with MIC 23.9 μM, which was approximately two times greater than that of the standard drug amoxicillin.

Keywords

Garcinia fuscaXanthonesFuscaxanthone IAntibacterial activityHelicobacter pylori

Supplementary material

12272_2013_266_MOESM1_ESM.pdf (1.7 mb)
Supplementary material 1 (PDF 1697 kb)
12272_2013_266_MOESM2_ESM.doc (218 kb)
Supplementary material 2 (DOC 218 kb)

Copyright information

© The Pharmaceutical Society of Korea 2013